By Soniya:
The Union Ministry of Health and Family Welfare has made a doctor’s prescription mandatory for the purchase of syrup-based medicines, including commonly used cough syrups, across India. The new rule came into effect immediately on June 16, 2026, following the publication of the Drugs (Fifth Amendment) Rules, 2026 in the Official Gazette.
The amendment modifies the Drugs Rules, 1945 by removing the term “syrups” from Schedule K, which previously allowed certain syrup formulations to be sold without a prescription. As a result, syrup-based medicines will now be subject to stricter regulatory control and can only be dispensed against a valid prescription from a registered medical practitioner.
Popular cough syrups such as Benadryl, Glycodin, Zedex, Tusq DX, Grilinctus, Cofsils Syrup, Himalaya Koflet, and Dabur Honitus are among the products affected by the new regulation. However, cough relief tablets, pills, and lozenges will continue to remain available over the counter under existing provisions.
The decision follows a draft notification issued in December 2025 and consultations with stakeholders, including the Drugs Technical Advisory Board (DTAB). The move is aimed at strengthening patient safety and ensuring responsible use of medicines.
The regulatory change comes in the backdrop of concerns over contamination-linked incidents involving syrup medicines in recent years. By bringing syrup formulations under prescription control, the government seeks to improve oversight, reduce misuse, and enhance public health safeguards across the country.
The amendment marks a significant step in India’s pharmaceutical regulatory framework, emphasizing safer medicine usage and greater accountability in drug distribution.
